


IPSEN IN BRIEF: 2025

We are a global biopharmaceutical company with a focus on transformative medicines in our three therapeutic areas:



Strategy

Entire focus on specialty care

Opportunities for further growth across three therapeutic areas

Global footprint

A well-balanced & expanded presence around the world

Strong balance sheet & cash generation

Free cash flow
>€750m ¹ in 2024
(+ 8.9%)



Expanding pipeline

A good mix of new molecules and lifecycle management

External-innovation strategy

Supported by a strong balance sheet and increased firepower

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovations and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit [ipsen.com](https://www.ipsen.com).

¹ Growth at constant exchange rates

Ipsen Key Figures

€3.4bn¹

Total sales
(2024)

31

Approved products
worldwide

100+

Countries where
Ipsen medicines
are marketed

FY 2024 Total Sales Growth: +9.9%¹

Oncology

Somatuline **1,121** | 5.6%
Cabometyx **595** | 13.3%
Decapeptyl **536** | -1.1%
Onivyde **202** | 23.7%
Tazverik **47** | 24.0%
Other Oncology **4** | -11.2%


Rare Disease

Bylvay **136**
Iqirvo **22**
Sohonos **21**

Neuroscience


Dysport Ax **399** | 8.3%
Dysport Tx **291** | 10.4%
Other Neuroscience **11** | 12.0%

Total Sales¹ (€M)



Geographic Breakdown

Total sales by region: 2024



North America
34%
of total sales

Europe
39%
of total sales

RoW
27%
of total sales

In this map, Europe is defined as the E.U., the U.K., Iceland, Liechtenstein, Norway and Switzerland.

¹ Growth at constant exchange rates

External Innovation in 2024

Early-stage

Late-stage

					
Global licensing in oncology	Strategic collaboration in neuroscience	License & R&D collaboration in oncology	Global licensing in oncology	Global licensing in immuno-oncology	Ex-U.S. licensing in pediatric oncology
Preclinical antibody drug conjugate (ADC) target	Up to two small molecules addressing RNA targets	Two preclinical precision T cell engagers from Marengo's Tri-STAR platform	Preclinical antibody-drug conjugate (ADC) with first-in-class potential	Preclinical novel T cell engager (TCE) with first-in-class potential	Regulatory submission of Tovorafenib in 2025

Focus of Generation Ipsen

Environment

GOALS¹

Greenhouse gas emissions by 2030
50% reduction in absolute Scope 1 & 2
20% reduction in absolute Scope 3



100% of global electricity sourced from renewable energy by 2025

Performance over 5 years

45%

% of reduction for
Scopes 1 & 2¹

25%

% of reduction for
Scopes 3¹

99.8%

Renewable
electricity across
all sites

People



Gender balance in
Global Leadership
Team

55%

of Women

Rating

S&P Global

Ranked 61

MSCI

Scored A



Scored 22.8

Khalid Deojee

Senior Manager, Investor Relations
+33 6 66 01 95 26
khalid.deojee@ipssen.com

¹ Based on the 2019 baseline



www.ipssen.com/investors